Isobutane

Isobutane

SCHEMBL454297

CC(C)C.O=COCl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL108080 0.84
Chloromethane SCHEMBL1814391 0.84
SCHEMBL102156 0.83
SCHEMBL5078402 0.80
Water SCHEMBL28057661 0.79
SCHEMBL27897205 0.79
SCHEMBL27528511 0.79
Methane SCHEMBL204080 0.79
SCHEMBL28559195 0.79
SCHEMBL27425167 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303872-A1 ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2011-04-06 EP claimed
EP-2181112-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS Merck Serono S.A. (CH) 2010-05-05 EP claimed
WO-2009148403-A1 ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2009-12-10 WO claimed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 WO claimed
US-4144131-A COUPLING, REACTION OF NUCLEOPHILIC AND ELECTROPHILIC GROUPS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1979-03-13 US claimed
US-11229637-B2 Nitrogen-containing heteroaryl compounds and methods of use thereof FIBROGEN, INC. (US) 2022-01-25 US disclosed
US-20210060000-A1 NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2021-03-04 US disclosed
US-10646482-B2 Nitrogen-containing heteroaryl compounds and methods of use thereof FIBROGEN, INC. (US) 2020-05-12 US disclosed
US-20190240213-A1 NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2019-08-08 US disclosed
WO-2019020810-A1 CRYSTALLINE FORM OF (2S)-2-[[(Z)-[-1-(2-AMINO-4-THIAZOLYL)-2-[[(3S)-2,2-DIMETHYL-4-OXO-1-(SULFOOXY)-3-AZETIDINYL]AMINO]-2-OXOETHYLIDENE]AMINO]OXY]-3-[4-[IMINO[(3R)-3- PIPERIDINYLAMINO]METHYL]PHENOXY]-PROPANOIC ACID AICURIS ANTI-INFECTIVE CURES GMBH (DE) 2019-01-31 WO disclosed
US-10092558-B2 Nitrogen-containing heteroaryl compounds and methods of use thereof FIBROGEN, INC. (US) 2018-10-09 US disclosed
WO-2017187245-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN OPTIMUS DRUGS (P) LIMITED (IN) 2017-11-02 WO disclosed
WO-2000040564-A1 N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE AVENTIS PHARMACEUTICALS INC. (US) 2000-07-13 WO disclosed
WO-2000040553-A1 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES AVENTIS PHARMACEUTICALS INC. (US) 2000-07-13 WO disclosed
WO-2000009544-A1 HEPTAPEPTIDE LHRH ANALOGS ABBOTT LABORATORIES (US) 2000-02-24 WO disclosed
WO-1998054208-A1 CONFORMATIONALLY CONSTRAINED PEPTIDOMIMETICS AS β-TURN TEMPLATES AND MODULATORS OF SH3 DOMAINS CADUS PHARMACEUTICAL CORPORATION (US) 1998-12-03 WO disclosed
EP-0503044-A1 PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF. POLIFARMA SPA (IT) 1992-09-16 EP disclosed
WO-1992006108-A1 PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF POLIFARMA S.P.A. (IT) 1992-04-16 WO disclosed
EP-0366193-A2 Novel antimicrobial quinolonyl lactams Norwich Eaton Pharmaceuticals, Inc. (US) 1990-05-02 EP disclosed
EP-0364344-A2 Novel peptidase inhibitors MERRELL PHARMACEUTICALS INC. (US) 1990-04-18 EP disclosed